EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Signal Peptide Engineering and Codon Optimization to Enhance α‐Gal A Activity for rAAV Gene Therapy of Fabry Disease

Siwu He, Li Yang, Ke Wan, Zhaoyue Zheng, Mi Leng, Chunmei Gan, Yu Liu iD, Lin Xiao, Jingya Ye, Zhian Chen, Jiao Zhou, C Alexander Valencia und 4 weitere

Journal of Inherited Metabolic Disease · 2026-03 · 49 (2)

DOI: 10.1002/jimd.70168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 09.03.2026. Verfasst von Siwu He und 15 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Geriatrics and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase, Genetic Therapy, Dependovirus. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, Key Research and Development Program of Sichuan Province, 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fabry disease is an X‐linked lysosomal storage disorder caused by mutations in the GLA gene, leading to deficient α‐galactosidase A (α‐Gal A) activity and pathological accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (Lyso‐Gb3) in various organs. To enhance α‐Gal A expression and secretion for recombinant adeno‐associated viral (rAAV) gene therapy, the signal peptide was engineered in HepG2 cells. Among 22 heterogeneous signal peptides, sp21 was identified and validated for this purpose. The enzyme activity of GLA with sp21 in conditioned media was 2.3 times higher than that with the wild‐type signal peptide. Furthermore, the human GLA gene was codon optimized (hGLAco), aiming to achieve increased hepatic expression and prevent gene silencing. The secreted α‐Gal A activity of hGLAco increased approximately 4‐fold in vitro. Finally, the hGLAco transgene with sp21 driven by a liver‐specific promoter was packaged in rAAV8 vectors and injected into Fabry mice. Compared with the wild‐type cDNA, the engineered GLA gene resulted in a 6.9‐fold increase in secreted α‐Gal A activity in Fabry mice, and toxic Lyso‐Gb3 accumulation in plasma and key tissues was effectively cleared. These findings demonstrate a promising strategy to develop a more efficient rAAV gene therapy for Fabry disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry Diseasealpha-GalactosidaseGenetic TherapyDependovirusCodonProtein Sorting SignalsHumansAnimalsMiceHep G2 CellsGenetic VectorsGene Therapy AgentsLiver

Stichwörter der Autor:innen

Fabry diseasecodon optimizationgene therapylysosomal storage diseaserecombinant adeno‐associated virussignal peptide

Substanzen

alpha-GalactosidaseCodonProtein Sorting SignalsGLA protein, human

Autor:innen und Institutionen

  • National Clinical Research Center for Geriatrics and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Geriatrics and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
  • Sichuan Real & Best Biotech Co., Ltd., Chengdu, China.
  • Cardiac Sciences Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  • Department of Cardiology, Cardiac Imaging and Target Therapy Lab, West China Hospital, Sichuan University, Chengdu, China.
  • Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, China.

ORCID-Profile: Yu Liu

Förderung

  • National Key Research and Development Program of China
  • Key Research and Development Program of Sichuan Province
  • 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
  • Natural Science Foundation of Sichuan Province

Zitieren

APA

He, S., Yang, L., Wan, K., Zheng, Z., Leng, M., Gan, C., Liu, Y., Xiao, L., Ye, J., Chen, Z., Zhou, J., Valencia, C. A., Abuammah, A., Chow, H. Y., Dong, B., & Chen, Y. (2026). Signal Peptide Engineering and Codon Optimization to Enhance α‐Gal A Activity for rAAV Gene Therapy of Fabry Disease. Journal of Inherited Metabolic Disease, 49(2). https://doi.org/10.1002/jimd.70168

Vancouver

He S, Yang L, Wan K, Zheng Z, Leng M, Gan C, et al. Signal Peptide Engineering and Codon Optimization to Enhance α‐Gal A Activity for rAAV Gene Therapy of Fabry Disease. Journal of Inherited Metabolic Disease. 2026;49(2). doi:10.1002/jimd.70168

BibTeX
@article{He2026,
  author = {He, Siwu and Yang, Li and Wan, Ke and Zheng, Zhaoyue and Leng, Mi and Gan, Chunmei and Liu, Yu and Xiao, Lin and Ye, Jingya and Chen, Zhian and Zhou, Jiao and Valencia, C Alexander and Abuammah, Aliah and Chow, Hoi Yee and Dong, Biao and Chen, Yucheng},
  title = {Signal Peptide Engineering and Codon Optimization to Enhance α‐Gal A Activity for rAAV Gene Therapy of Fabry Disease},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2026},
  volume = {49},
  number = {2},
  doi = {10.1002/jimd.70168}
}
Kostenlos starten →